Gilead Sciences, INC. (GILD) — 10-Q Filings

All 10-Q filings from Gilead Sciences, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Gilead Swings to Profit on Reduced R&D Impairments — Nov 7, 2025 Risk: medium
Gilead Sciences, Inc. reported a significant turnaround in its financial performance for the nine months ended September 30, 2025, achieving a net income of $6.
Gilead's Q2 Sales Dip Amidst Steady Royalty Income — Aug 7, 2025 Risk: medium
Gilead Sciences, Inc. reported product sales of $6.60 billion for the second quarter of 2025, a decrease from $6.70 billion in the second quarter of 2024. For t
Gilead Sciences Files Q1 2025 10-Q Report — May 7, 2025 Risk: low
Gilead Sciences, Inc. filed its quarterly report on Form 10-Q for the period ending March 31, 2025. The filing details financial performance and operational upd
Gilead Sciences Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
Gilead Sciences, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third qu
Gilead Sciences Files 10-Q for Q2 2024 — Aug 8, 2024 Risk: low
Gilead Sciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first half of th
Gilead Sciences, Inc. Files Quarterly Report (10-Q) for Period Ending March 31, 2024 — May 8, 2024 Risk: medium
GILEAD SCIENCES, INC. (GILD) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Gilead Sciences, Inc. reported its financial results for the quarter e

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX